Giammei Carolina, Balber Theresa, Felber Veronika, Dillinger Thomas, Cardinale Jens, Brandt Marie R, Stingeder Anna, Mitterhauser Markus, Egger Gerda, Mindt Thomas L
Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, c/o Sekretariat Nuklearmedizin, Währiger Gürtel 18-20, 1090 Vienna, Austria.
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Währinger Straße 42, 1090 Vienna, Austria.
Pharmaceuticals (Basel). 2025 Jul 3;18(7):1002. doi: 10.3390/ph18071002.
: Radiolabeled biomolecules specifically targeting overexpressed structures on tumor cells hold great potential for prostate cancer (PCa) imaging and therapy. Due to heterogeneous target expression, single radiopharmaceuticals may not detect or treat all lesions, while simultaneously applying two or more radiotracers potentially improves staging, stratification, and therapy of cancer patients. This study explores a dual-tracer SPECT approach using [In]In-RM2 (targeting the gastrin-releasing peptide receptor, GRPR) and [Tc]Tc-PSMA-I&S (targeting the prostate-specific membrane antigen, PSMA) as a proof of concept. To mimic heterogeneous tumor lesions in the same individual, we aimed to establish a dual xenograft mouse model for preclinical evaluation. : CHO-K1 cells underwent lentiviral transduction for human GRPR or human PSMA overexpression. Six-to-eight-week-old female immunodeficient mice (NOD SCID) were subsequently inoculated with transduced CHO-K1 cells in both flanks, enabling a dual xenograft with similar target density and growth of both xenografts. Respective dual-isotope imaging and γ-counting protocols were established. Target expression was analyzed by Western blotting. : studies showed similar target-specific binding and internalization of [In]In-RM2 and [Tc]Tc-PSMA-I&S in transduced CHO-K1 cells compared to reference lines PC-3 and LNCaP. However, imaging showed negligible tumor uptake in xenografts of the transduced cell lines. analysis indicated a loss of the respective biomarkers in the xenografts. : Although the technical feasibility of a dual-tracer SPECT imaging approach using In and Tc has been demonstrated, the potential of [Tc]Tc-PSMA-I&S and [In]In-RM2 in a dual-tracer cocktail to improve PCa diagnosis could not be verified. The animal model, and in particular the transduced cell lines developed exclusively for this project, proved to be unsuitable for this purpose. The / experiments indicated that results from an model may not necessarily be successfully transferred to an setting. To assess the potential of this dual-tracer concept to improve PCa diagnosis, optimized models are needed. Nevertheless, our strategies address key challenges in dual-tracer applications, aiming to optimize future SPECT imaging approaches.
放射性标记的生物分子特异性靶向肿瘤细胞上过度表达的结构,在前列腺癌(PCa)成像和治疗方面具有巨大潜力。由于靶点表达的异质性,单一放射性药物可能无法检测或治疗所有病灶,而同时应用两种或更多种放射性示踪剂可能会改善癌症患者的分期、分层和治疗。本研究探索了一种使用[铟]In-RM2(靶向胃泌素释放肽受体,GRPR)和[锝]Tc-PSMA-I&S(靶向前列腺特异性膜抗原,PSMA)的双示踪剂SPECT方法作为概念验证。为了模拟同一个体中的异质性肿瘤病灶,我们旨在建立一种用于临床前评估的双异种移植小鼠模型。:CHO-K1细胞经慢病毒转导以实现人GRPR或人PSMA的过表达。随后,将转导后的CHO-K1细胞接种到6至8周龄雌性免疫缺陷小鼠(NOD SCID)的双侧腹股沟,从而实现具有相似靶点密度且两种异种移植瘤均生长的双异种移植。建立了各自的双同位素成像和γ计数方案。通过蛋白质免疫印迹分析靶点表达。:研究表明,与参考细胞系PC-3和LNCaP相比,[铟]In-RM2和[锝]Tc-PSMA-I&S在转导后的CHO-K1细胞中具有相似的靶点特异性结合和内化。然而,成像显示转导细胞系异种移植瘤中的肿瘤摄取可忽略不计。分析表明异种移植瘤中各自的生物标志物有所丢失。:尽管已证明使用铟和锝的双示踪剂SPECT成像方法在技术上可行,但[锝]Tc-PSMA-I&S和[铟]In-RM2在双示踪剂混合物中改善PCa诊断的潜力无法得到验证。该动物模型,尤其是专门为该项目开发的转导细胞系,被证明不适用于此目的。/实验表明,来自模型的结果不一定能成功转化到临床环境中。为了评估这种双示踪剂概念改善PCa诊断的潜力,需要优化的模型。尽管如此,我们的策略解决了双示踪剂应用中的关键挑战,旨在优化未来的SPECT成像方法。